NovoCure Ltd

NovoCure reported record second quarter 2026 financial results, with net revenues increasing 16% year-over-year to $183.6 million, driven by 18% global active patient growth. The company achieved an Adjusted EBITDA of $10.8 million and reduced its net loss to $15.7 million. Key operational achievements include receiving CE Mark for Optune Pax for pancreatic cancer, with Germany being the first EU market for launch. Consequently, NovoCure raised its full-year 2026 net revenue guidance to $710 million - $725 million and Adjusted EBITDA guidance to $0 million - $15 million.

NovoCure Ltd reported Q2 2026 net revenues of $183.6 million, a 15.6% increase year-over-year, with the net loss significantly narrowing to $15.7 million from $40.1 million in Q2 2025. For the first six months of 2026, net revenues grew to $357.6 million, though the net loss widened to $86.8 million. The company also updated its 2024 Omnibus Incentive Plan, adding 9 million ordinary shares for grant, and opted not to draw additional tranches from its senior secured credit facility.

NovoCure announced that its medical device, Optune Pax®, has received CE Mark approval for the treatment of adult patients with locally-advanced pancreatic cancer of exocrine origin. The approval is for use alongside gemcitabine and nab-paclitaxel chemotherapy. This designation is supported by positive results from the Phase 3 PANOVA-3 clinical trial, which demonstrated a statistically significant improvement in overall survival and a significant delay in pain progression for patients treated with Optune Pax. The company plans to launch Optune Pax in Germany in the coming weeks.

NovoCure announced topline results from its Phase 3 TRIDENT trial for newly diagnosed glioblastoma, which did not meet its primary endpoint of statistically significant improvement in overall survival. The Early Start Arm had a median overall survival of 17.7 months compared to 17.5 months in the Maintenance Start Arm. Despite the primary endpoint miss, TTFields therapy was well-tolerated with no new safety signals, and the results have been accepted for presentation at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting.

NovoCure Limited held its Annual General Meeting on June 3, 2026, where shareholders elected eleven directors to serve until the 2027 annual meeting. Key proposals approved included the ratification of Kost Forer Gabbay & Kasierer as the independent auditor for 2026, a non-binding advisory vote on executive compensation, and the Company's Amended and Restated 2024 Omnibus Incentive Plan. Approximately 81.01% of total shares entitled to vote were present and voted on the proposals.

NovoCure reported Q1 2026 net revenues of $174.1 million, a 12% increase year-over-year, driven by global growth in Optune Gio. The company posted a net loss of $71.1 million, primarily due to a $43 million share-based compensation expense triggered by the U.S. FDA approval of Optune Pax. Optune Pax was approved by the U.S. FDA and launched for locally advanced pancreatic cancer, with 169 prescriptions received. The company also updated its full-year 2026 revenue guidance to $690 million - $710 million and Adjusted EBITDA guidance to $(15) million - $0 million.

NovoCure Ltd. reported a net loss of $(71.1) million for Q1 2026, significantly wider than the $(34.3) million loss in Q1 2025, despite a 12.3% increase in net revenues to $174.1 million. The increased loss was primarily driven by a $43.4 million share-based compensation expense related to the USFDA approval of Optune Pax for pancreatic cancer on February 11, 2026. The company also noted it did not draw additional tranches from its senior secured credit facility.

NovoCure Ltd. announced a new employment agreement for Francis Leonard, effective January 1, 2026. Leonard will continue to serve as the Chief Executive Officer of the Novocure Group, with his formal employment relationship being with Novocure GmbH, a Swiss subsidiary. This new agreement supersedes his prior employment letter agreement dated September 1, 2020, and recognizes his years of service since June 14, 2010.

NovoCure Limited has appointed Uri Weinberg, M.D., Ph.D., as its Chief Medical Officer, effective April 8, 2026. Dr. Weinberg will assume this new role in addition to his existing responsibilities as Chief Innovation Officer. In connection with this expanded role, his monthly salary will increase by CHF 5,000, as outlined in a letter agreement dated April 7, 2026. This move reflects the company's strategic alignment of its medical and innovation leadership under a single executive, potentially streamlining decision-making in clinical development and product strategy.